Impella ECP is the world’s smallest heart pump. It achieves peak flows greater than 3.5 L/min and is delivered through a slender-profile sheath. It is un-sheathed in the descending aorta and expands ...
DANVERS, Mass., Oct. 28, 2024 /PRNewswire/ -- Results were presented at Transcatheter Cardiovascular Therapeutics (TCT) 2024 conference from the first completed pivotal trial on patients supported ...
Abiomed, Inc. ABMD announced receipt of the FDA’s breakthrough device designation for its Impella ECP expandable percutaneous heart pump. Bestowing of the designation implies that the FDA will ...
DANVERS, Mass.--(BUSINESS WIRE)--The United States Food and Drug Administration (FDA) has granted breakthrough device designation to Abiomed’s (NASDAQ: ABMD) Impella ECP expandable percutaneous heart ...
Abiomed Inc. is one of a number of companies whose share prices took a hit in the early days of the COVID-19 pandemic, but the company has since rebounded, thanks in part to the news that the FDA has ...
Abiomed Inc. is one of a number of companies whose share prices took a hit in the early days of the COVID-19 pandemic, but the company has since rebounded, thanks in part to the news that the FDA has ...
Impella ECP is a technology of Abiomed, part of Johnson & Johnson MedTech, and the global leader in heart recovery. The pivotal investigational device exemption (IDE) study, which enrolled 256 ...
DANVERS, Mass.--(BUSINESS WIRE)--Abiomed (NASDAQ: ABMD) announces the United States Food and Drug Administration (FDA) has approved the company's investigational device exemption application to start ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback